...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen/Eisai Scrap Aducanumab

"Seems to be for early-onset of the AD. How would this compare to the 250 patients in the BOM trial?"

According to this website:

"In the initial study data establishing the MoCA, normal controls had an average score of 27.4, compared with 22.1 in people with mild cognitive impairment (MCI) and 16.2 in people with Alzheimer's disease."

The 246 patients randomized with baseline MoCA <25 in BETonMACE ranged from MoCA score of 7 to 25, with median 22 (see ACC poster). So about half have scores of 22 to 25, and the other half have scores of 7 to 22. 

BearDownAZ

 

Share
New Message
Please login to post a reply